Biofrontera (BFRI) vs CytoMed Therapeutics (GDTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biofrontera (BFRI) has outperformed CytoMed Therapeutics (GDTC) over the past year, losing 28.4% versus a loss of 59.8%. Biofrontera is the larger company by market cap ($9.5 million vs $9.0 million), about 1.1 times the size, while CytoMed Therapeutics is growing revenue faster (+395.9% vs +11.7%). Biofrontera converts more of its revenue into profit, with a net margin of -25.3% versus -1227.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | GDTC |
|---|---|---|
| Share price | $0.53 | $0.755 |
| Market cap | $9.51M | $9.01M |
| 1-day change | -7.02% | -2.33% |
| YTD return | -7.02% | -43.45% |
| 1-year return | -28.38% | -59.84% |
| 5-year return | -99.66% | — |
| Forward P/E | 1.32 | — |
| EPS (TTM) | $-0.26 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.70M | $252.26K |
| Revenue growth (YoY) | +11.75% | +395.88% |
| Net income (latest FY) | $-10.54M | $-3.10M |
| Operating margin | -27.21% | — |
| Net margin | -25.26% | -1227.07% |
| 52-week high | $1.66 | $2.12 |
| 52-week low | $0.53 | $0.68 |
| Distance from 52-week high | -68.07% | -64.39% |
| Analyst consensus | none | none |
| Avg. price target upside | +1032.08% | +450.99% |
| Average volume | 429.04K | 15.69K |
| Shares outstanding | 17.95M | 11.93M |
| Employees | 84 | 42 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed GDTC by 31.5 percentage points over the past year.
- Biofrontera is more profitable, keeping -25.3 cents of every revenue dollar as net income versus -1227.1 cents for CytoMed Therapeutics.
- CytoMed Therapeutics grew revenue faster in its latest fiscal year (+395.88% vs +11.75%).
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
BFRI vs GDTC FAQ
Which is bigger, Biofrontera or CytoMed Therapeutics?
Biofrontera (BFRI) is larger, with a market capitalization of $9.51M compared with $9.01M for CytoMed Therapeutics (GDTC).
Which stock has performed better over the past year, BFRI or GDTC?
BFRI returned -28.38% over the past 12 months, compared with -59.84% for GDTC (price return, excluding dividends). Past performance does not predict future results.
Are Biofrontera and CytoMed Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.